License from Gilead grants AbTherx worldwide rights to a novel human therapeutic antibody discovery platform
The licensed technologies enable the development of a clinically validated bispecific antibody format most similar to native antibodies, use natural mechanisms to generate long CDR3 antibodies to improve the chance of success against challenging drug targets such as GPCRs and ion channels, and increase access to transgenic mice expressing full human antibody diversity.
ギリアドが二重特異性抗体開発の技術を取得しました。二重特異性抗体は、アムジェンのビーリンサイトを始めとする、次代のがんの開発の重要なトレンド。簡単に言うと2つの抗体をくっつけたもので、2028年に300億米ドル規模に到達すると予想されてます。
License from Gilead grants AbTherx worldwide rights to a novel human therapeutic antibody discovery platform
The licensed technologies enable the development of a clinically validated bispecific antibody format most similar to native antibodies, use natural mechanisms to generate long CDR3 antibodies to improve the chance of success against challenging drug targets such as GPCRs and ion channels, and increase access to transgenic mice expressing full human antibody diversity.
二重特異性抗体とDGK inhibitorの併用など、妄想が膨らんでしまいます。